Skip to main content

Table 3 Lipids significantly associated with SCA burden. All lipids were manually annotated using MS/MS data

From: Lipidomic analysis reveals metabolism alteration associated with subclinical carotid atherosclerosis in type 2 diabetes

mz

rt

Lipids

q-value

Beta

n

Analysis

1289.1869

597.06

Dimer(CE(18:2):CE(16:1)) + NH4

0.021

0.4 [0.22,0.57]

285

T2D no DLP

494.324

88.44

LPC(16:1) + H

0.047

0.35 [0.16,0.54]

281

T2D no DLP

494.3241

98.07

LPC(O-16:2);O + H

0.048

0.34 [0.15,0.52]

285

T2D no DLP

504.3084

130.8

LPE(20:3) + H

0.03

0.43 [0.22,0.64]

282

Smokers with T2D

570.3558

131.32

LPC(22:5) + H

0.046; 0.047

0.38 [0.17,0.58]; 0.34 [0.15,0.53]

245

Smokers with T2D; T2D no DLP

572.3709

153.57

LPC(22:4) + H

0.041

0.35 [0.17,0.54]

285

Smokers with T2D

577.5182

514.69

DG(18:1_16:0)-H2O + H

0.047

0.3 [0.14,0.47]

285

T2D no DLP

578.5869

517.93

Mix Cer(38:1);O − main Cer(m18:1/20:0) + H

0.049; 0.047

0.25 [0.11,0.39]; 0.29 [0.13,0.45]

264

T2D no DLP; Smokers with T2D

608.5246

479.45

DG(16:1_18:2_0:0) + NH4

0.047

0.28 [0.13,0.44]

285

T2D no DLP

612.556

515.31

DG(18:1_16:0_0:0) + NH4

0.047

0.29 [0.13,0.46]

285

T2D no DLP

621.5448

516.82

DG(18:1_18:1) + H

0.047

0.31 [0.14,0.47]

270

T2D no DLP

640.6023

596.54

CE(16:1) + NH4

0.03; 0.013

0.42 [0.21,0.63]; 0.44 [0.26,0.63]

244

Smokers with T2D; T2D no DLP

648.6288

539.32

Cer(d18:1/24:1) + H

0.047

0.31 [0.14,0.48]

285

T2D no DLP

732.5531

459.75

PC(32:1) + H

0.042

0.35 [0.17,0.54]

285

Smokers with T2D

828.6096

480.61

PC(38:3);O + H

0.041

− 0.41 [− 0.62,− 0.19]

285

Smokers with T2D

838.6313

499.04

PC(40:4) + H

0.01; 0.047

0.48 [0.28,0.68]; 0.33 [0.15,0.51]

285

Smokers with T2D; T2D no DLP

846.5993

428.71

PC(41:7) + H

0.01; 0.047

− 0.5 [− 0.72,− 0.28]; − 0.35 [− 0.54,− 0.16]

259

Smokers with T2D; T2D no DLP

866.6634

514.92

PC(42:4) + H

0.022

0.44 [0.23,0.64]

279

Smokers with T2D

397.3826

607.15

Sterol lipid − C29H50O

0.044

− 0.37 [− 0.56, − 0.17]

142

T1D

768.556

496.59

PE(18:0_20:3)-H

0.048

0.3 [0.12,0.49]

269

Smokers with T2D

776.5454

461.5

Mix PC (32:1) − PC(16:1_16:0) + HCOO– & PC(18:1/14:0) + HCOO–

0.018

0.39 [0.2,0.59]

269

Smokers with T2D

778.5611

482.89

PC(16:0/16:0) + HCOO–

0.032

0.39 [0.17,0.6]

269

Smokers with T2D

802.5609

465.5

Mix PC(34:2) − PC(18:2_16:0) + HCOO– & PC(18:1_16:1) + HCOO–

0.049

0.34 [0.12,0.55]

269

Smokers with T2D

804.5765

484.96

PC(18:1_16:0) + HCOO–

0.048

0.36 [0.14,0.57]

269

Smokers with T2D

807.586

484.96

CerPE(39:1;O4) + HCOO-

0.048

0.36 [0.14,0.57]

269

Smokers with T2D

815.6307

497.13

SM(d18:1/21:1) + HCOO–

0.049

− 0.3 [− 0.49,− 0.11]

269

Smokers with T2D

836.5458

439.16

PC(15:0_22:6) + HCOO-

0.05

− 0.33 [− 0.55,− 0.12]

267

Smokers with T2D

856.608

494.63

Mix PC(38:3) − main PC(18:2_20:1) + HCOO– & PC(18:1_20:2) + HCOO–

0.049

0.29 [0.11,0.47]

269

Smokers with T2D

882.624

500.35

PC(22:4_18:0) + HCOO–

0.049

0.36 [0.14,0.58]

269

Smokers with T2D

  1. m/z, mass-to-charge ratio value; rt, retention time; q-value, list of corrected p-values for each analysis where the lipid is considered to be significant, the p-values are obtained from the student’s t-tests performed in linear models; Beta, list of linear regressors for each significant analysis with their 95% confidence interval between brackets; n, number of observations in each model; Analysis, analysis where the lipid is considered significant (subjects with T1D–T1D, subjects with T2D–T2D, subjects with T2D without dyslipidemia—T2D no DLP, and smokers with T2D—Smokers with T2D). All lipids were acquired in positive acquisition mode except the ones with the adduct [M + HCOO–]
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840